- Home
- ANVS vs NEUE Comparison
ANVS vs NEUE Comparison
Compare ANVS & NEUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- NEUE
- Stock Information
- Founded
- ANVS 2008
- NEUE 2015
- Country
- ANVS United States
- NEUE United States
- Employees
- ANVS N/A
- NEUE N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- NEUE
- Sector
- ANVS Health Care
- NEUE
- Exchange
- ANVS Nasdaq
- NEUE NYSE
- Market Cap
- ANVS 54.6M
- NEUE 61.3M
- IPO Year
- ANVS 2020
- NEUE 2021
- Fundamental
- Price
- ANVS $2.64
- NEUE $6.81
- Analyst Decision
- ANVS Strong Buy
- NEUE Hold
- Analyst Count
- ANVS 5
- NEUE 1
- Target Price
- ANVS $30.25
- NEUE $7.00
- AVG Volume (30 Days)
- ANVS 570.5K
- NEUE 5.3K
- Earning Date
- ANVS 08-14-2025
- NEUE 08-06-2025
- Dividend Yield
- ANVS N/A
- NEUE N/A
- EPS Growth
- ANVS N/A
- NEUE N/A
- EPS
- ANVS N/A
- NEUE N/A
- Revenue
- ANVS N/A
- NEUE $907,349,000.00
- Revenue This Year
- ANVS N/A
- NEUE $33.99
- Revenue Next Year
- ANVS N/A
- NEUE $5.90
- P/E Ratio
- ANVS N/A
- NEUE N/A
- Revenue Growth
- ANVS N/A
- NEUE N/A
- 52 Week Low
- ANVS $1.11
- NEUE $3.79
- 52 Week High
- ANVS $17.88
- NEUE $7.66
- Technical
- Relative Strength Index (RSI)
- ANVS 54.28
- NEUE 50.30
- Support Level
- ANVS $2.73
- NEUE $6.77
- Resistance Level
- ANVS $3.08
- NEUE $6.83
- Average True Range (ATR)
- ANVS 0.32
- NEUE 0.05
- MACD
- ANVS -0.06
- NEUE -0.00
- Stochastic Oscillator
- ANVS 29.41
- NEUE 37.50
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About NEUE NEUEHEALTH INC
NeueHealth Inc is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated healthcare. It consists of two reportable segments: NeueCare - it's a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. NeueSolutions - it's a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers to thrive in performance-based arrangements.